New strategies for patients with limited-stage small-cell lung cancer.
Famke L Schneiders, Suresh Senan
https://pubmed.ncbi.nlm.nih.gov/39146945/Actively Recruiting
Led by Shandong Cancer Hospital and Institute · Updated on 2021-04-29
534
Participants Needed
2
Research Sites
104 weeks
Total Duration
Researchers are conducting a phase III clinical trial to compare two approaches for managing patients with limited-stage small cell lung cancer LS-SCLC who have achieved remission after first-line chemoradiotherapy. The study aims to evaluate the effectiveness and safety of prophylactic cranial irradiation PCI versus MRI surveillance in preventing cancer spread to the brain. While PCI is used to reduce brain metastasis, MRI surveillance may lower side effects and could be similarly effective by delaying radiation until brain metastases appear. Participants are randomly assigned to one of two groups. One group receives PCI with recommended hippocampal protection, delivered within six weeks after first-line treatment at a total dose of 25 Gy over ten sessions. Brain MRI scans are performed every three months for the first two years, then every six months until brain metastases occur. The other group undergoes regular brain MRI scans on the same schedule without PCI, and if brain metastases develop, they receive brain radiotherapy and systemic treatment with continued MRI monitoring. During the study, participants will have ongoing brain MRI scans and clinical assessments to monitor disease progression and side effects. Researchers will measure overall survival up to two years after randomization, along with progression-free survival, rates of brain metastasis, neurocognitive impairment, and one- and three-year survival rates. The study includes careful safety monitoring and follow-up to evaluate the benefits and risks of each approach in this patient population.
CONDITIONS
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy
J
Jinming Yu, PhD
X
Xiangjiao Meng, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shandong Cancer Hospital and Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 weeks for prophylactic cranial irradiation; MRI surveillance involves ongoing imaging over time
Participants receive either prophylactic cranial irradiation or undergo MRI surveillance after first-line chemoradiotherapy remission.
For PCI: 10 daily visits over 2 weeks; For MRI surveillance: MRI every 3 months for 2 years, then every 6 months until brain metastasis occur
Duration - Up to 2 years
Participants are monitored for brain metastasis and overall survival with regular MRI scans continuing after treatment ends.
MRI every 3 months for first 2 years, then every 6 months thereafter
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Famke L Schneiders, Suresh Senan
https://pubmed.ncbi.nlm.nih.gov/39146945/Shandong Cancer Hospital and Institute
Lead Sponsor